Nantes, France – September 20, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the scientific advances from its research programs have been selected for presentation at upcoming European and American congresses: at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20 – 23), the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1 – 5) and the 15th PEGS Europe (Protein & Antibody Engineering Summit) in Lisbon, Portugal (November 14 – 16). The communications will focus on the latest advances in the Company’s research programs in immuno-oncology: CLEC-1 (new myeloid immune checkpoint), CYTOMASK (new innovative cytokine unmasking technology), BiCKI®-IL-7 (bifunctional targeting PD-1 and IL-7) and Tedopi® (epitope-based T cell activation therapeutic cancer vaccine).